Claims:

1. A pharmaceutical composition for the treatment of the risk factors of syndrome X of Reaven comprising as active ingredient a compound selected among somatostatin or one of its analogs (as herein defined), diazoxide or one of its analogs (as herein defined), cyclothiazideor one of its analogs(as herein defined) and metformin.

2. A pharmaceutical composition according to Claim 1, further comprising an additional compound.

3. A pharmaceutical composition according to Claim 1, Further comprising an additional compound having an additional pharmaceutical effect.

4. A pharmaceutical composition according to Claim 2 ~~or 3~~ wherein the additional compound is selected among carriers, solvents and emulgamators.

5. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the analog of somatostatin is Octreotide.

6. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the analog of somatostatin is Vapreotide.

7. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the analog of somatostatin is Lanreotide.

8. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the analogs of somatostatin are Cyclopeptide somatostatin analogues selected among :

Cyclo[Pro-Phe-D-Trp-Lys-Thr-Phe]
Cyclo[N-Me-Ala-Tyr-D-Trp-Lys-Val-Phe]
Cyclo[Pro-Ala-D-Trp-Lys-Thr-Phe]
Cyclo[Pro-Tyr-D-Trp-Lys-Thr-Phe]
Cyclo[Pro-Phe-D-Trp-Lys-δ-aminobutyric-Phe]
Cyclo[N-Me-Ala-Phe-D-Trp-Lys-Thr-Phe]
Cyclo[Pro-Phe-D-Trp-Lys-Val-Phe]
Cyclo[D-Ala-D-Phe-D-Trp-L-Lys-D-Thr-N-Me-D-Phe]
Cyclo[Pro-Phe-D-Trp-Lys-Thr(Bzl)] (Bzl = (a)
Cyclo[Pro-Phe-D-Trp-Lys-Thr-Phe]
Cyclo[Pro-D-Phe-D-Trp-Lys-Thr(Bzl)]
Cyclo[Ahep-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Tyr-Thr-Ser] (Ahep =(b)
Cyclo[Ahep-Phe-D-Trp-Lys-Thr(Bzl)]
Cyclo[Ahep-Phe-D-Trp-Lys-Thr]

Cyclo[Ahep-Phe-D-Trp-Lys-Ser(Bzl)]
Cyclo[Ahex-Phe-D-Trp-Lys-Thr(Bzl)] (Ahex = (c)
Cyclo[Aoct-Phe-D-Trp-Lys-Thr(Bzl)] (Aoct = (d)
Cyclo[Ala-Cys-Phe-D-Trp-Lys-Thr-Cys]

(a) Bzl = benzyl
(b) Ahep = 7-aminoheptanoyl
(c) Ahex = 6-aminohexanoyl
(d) Aoct = 8-amino-octanoyl;

9. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-[Cys-Phe-D-Trp-Lys-Thr-Cys]-Thr-ol

10. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Nal-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH_2 (Nal = (1)

11. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Nal-NH_2

12. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-[Cys-Tyr-D-Trp-Lys-Thr-Cys]-Nal-NH_2

13. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Nal-NH_2 (Abu = (2)

14. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-[Cys-Tyr-D-Trp-Lys-Ser-Cys]-Nal-NH_2

15. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Nal-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Nal-NH_2

16. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
c(Ahep-Trp-D-Trp-Lys-Thr-Phe) (Ahep = (3)

17. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH_2 (Cpa = (4)

18. A pharmaceutical composition according to ~~any of claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH_2

19. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH_2

20. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-Phe-Phe-D-Trp-Lys-Val-Phe-Thr-NH_2

21. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-D-Nal-NH_2

22. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-Ala-Phe-D-Trp-Lys-Ala-Nal-NH_2

23. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-Phe-Phe-D-Trp-Lys-Val-Phe-Thr-NH_2

24. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH_2

25. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analog is:
D-Phe-Phe-Tyr-D-Trp-Lys-Val-Phe-D-Nal-NH2

26. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analogs are polypeptides of the formula:
X-Lys-Asn-Phe-Phe-A-Lys-Thr-Phe-Thr-Ser-Y
wherein A is L- or D-Trp,
X is H-$(Aeg)_m$-Cys- or H-$(Aeg)_m$-Ala-Gly-Cys-,
Y is -Cys-$(Aeg)_n$-OH or
X and Y taken together are a 2-aminoethyl-glycyl group in the ring position and
m and n are 0, 1, 2, provided that
m and n are at least 1,
and their cyclic disulfide derivatives.

27. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analogs are peptides of the formula:

Bmp-Lys-X-Phe-Phe-trp-Lys-Thr-Phe-Thr-Y-Cys-OH
3 4 5 6 7 8 9 10 11 12 13 14

in which

Bmp represents the desaminocysteine radical,

X represents Asn,

trp represents D-Trp that may be substituted in the benzene ring by a halogen atom, and

Y represents the radical of an alpha-(lower alkyl)amino-(lower alkyl)-carboxylic acid having a minimum of 4 and a maximum of 8 carbon atoms, in which the two lower alkyl radicals can be connected to one another with a single C-C bond, an oxygen atom or a sulphur (II) atom.

28. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analogs are cyclic octapeptides of the formula

Asn-Phe-Phe-Trp-Lys-Thr-Phe-Gaba(Ar)
5 6 7 8 9 10 11 12

in which

Trp represents L-Trp or D-Trp, in which the benzene ring may be substituted by a fluorine atom, and

Gaba(Ar) represents the residue of a γ-aminobutyric acid substituted by a cyclic hydrocarbyl radical Ar selected from the group consisting of cyclohexyl; phenyl optionally substituted by halogen, nitro or phenoxy; and naphthyl optionally substituted by halogen.

29. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analogs are compounds of formula

H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-R_8
-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-R_{18}-R_{19}-Phe-Phe-D
-Trp-Lys-Thr-R_{25}-R_{26}-R_{27}-R_{28}-OH wherein R_8 is

Met or Leu, R_{18} is Lys or des R_{18}, R_{19} is Asn or des R_{19}, R_{25} is Phe or Tyr, R_{26} is Thr or des R_{26}, R_{27} is Ser or D-Ser and R_{28} is D-Cys or Cys.

30. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ CLAIM 1, wherein the somatostatin analogs are compounds of formula

H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-R_8-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-R_{18}-R_{19}-Phe-Phe-D-Trp-Lys-Thr-R_{25}-R_{26}-R_{27}-R_{28}-OH wherein R_8 is Met or Leu, R_{18} is Lys or des R_{18}, R_{19} is Asn or des R_{19}, R_{25} is Phe or Tyr, R_{26} is Thr or des R_{26}, R_{27} is Ser or D-Ser and R_{28} is D-Cys or Cys, or the linear version thereof where the disulfide bridge is replaced by hydrogen.

31. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ CLAIM 1, wherein the somatostatin analogs are cyclic hexapeptides of the formula

-X - Phe-D-Trp-Lys-Y-Phe-

in which X represents the radical of an L-aminoacid of the formula



in which A and B are identical or different and denote alkyl having 1 to 3 carbon atoms, or A and B together represent a saturated, unsaturated or aromatic monocyclic or bicyclic structure having 3 to 6 carbon atoms,
n denotes 0 or 1, and
Y represents an aliphatic or aromatic L-aminoacid the side-

chair of which can be hydroxylated, said amino acid being selected from the group consisting of L-alanine, L-serine, L-valine, L-leucine, L-isoleucine, L-phenylalanine and L-tyrosine.

32. A pharmaceutical composition according to ~~any of claims~~ Claim 1 to 4, wherein the somatostatin analogs are N-acyl-polypeptides of formula,



wherein

"Acyl" is a group of formula $R^{I}CO-$ wherein R^{I} is C_{1-20} alkyl or phenyl; a group of formula $R^{II}SO_2-$ wherein R^{II} is C_{1-20}-alkyl, phenyl or tolyl; a group



wherein

R^{III} and R^{IV} are each independently hydrogen or C_{1-10}alkyl; or biotinyl,

A is hydrogen or C_{1-3}alkyl,

>N-CH(Z)-CO- is an (L)- or (D)-phenylalanine residue optionally ring-substituted by NO_2, or an (L) or (D)-norleucine residue,

whereby

Z in >N-CH(Z)-CO- represents the remainder of said residue,

B is -Phe- optionally ring-substituted by NO_2,

F is a group of formula



wherein R_4 is hydrogen or a group of formula

$-CH(R_5)-X$,

R_5 is $CH_3CH(OH)-$, i-butyl or benzyl

X is a group of formula $-COOR_1$,

$-CH_2OR_2$ or



wherein R_1, R_6 and R_7 are each hydrogen or C_{1-3}alkyl, and

R_2 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester,

the group $-CH(R_5)-X$ having the (D)- or (L)-configuration, and

Y_1 and Y_2 are each hydrogen or together represent a direct bond, whereby the residue resides in the 2- and 7-position each indepen-dently have the (L)- or (D)-configuration,

and with the proviso that:

i) (L)- and/or (D)-cysteine residues are present at the 2- and 7-positions only.

33. A pharmaceutical composition according to ~~any of~~ claim 1 ~~1 to 4~~, wherein the somatostatin analogs are polypeptides of the formula



wherein

A is C_{1-12}alkyl, C_{7-10}phenylalkyl or a group of formula RCO-, whereby

i) R is hydrogen, C_{1-11}alkyl, phenyl or C_{7-10}phenylalkyl, or

ii) RCO- is a) an L- or D-phenylalanine residue optionally ring-substituted by halogen and/or C_{1-3}alkyl,

b) H-Asn-, or

c) H-Nle-Asn-,

the α-amino group of amino acid residues a) and b) and the N-terminal amino group of dipeptide residues c) being optionally mono- or di-C_{1-12}alkylated,

A' is hydrogen or, when A is C_{1-12}alkyl or C_{7-10}phenylalkyl, also C_{1-12}alkyl or C_{7-10}phenylalkyl,

B is -Phe-optionally ring-substituted by halogen and/or C_{1-3}alkyl,

C is -(L)- or -(D)-Trp- optionally α-N-methylated and optionally benzene-ring-substituted by halogen and/or C_{1-3}alkyl,

D is -Lys- optionally α-N-methylated and optionally Σ-N-C_{1-3}-alkylated,

E is -Thr- or -Ala- each in (D)- or (L)-form and each being optionally α-N-methylated,

F is a group of formula $-COOR_1$, $-CH_2OR_2$, $-CO-N(R_3)(R_4)$ or



wherein R_1 is hydrogen or C_{1-3}alkyl,

R_2 is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester,

R_3 is hydrogen, C_{1-3}alkyl, phenyl or C_{7-10}-phenylalkyl,

R_4 is hydrogen, C_{1-3}alkyl or, when R_3 is hydrogen or methyl, also a group of formula $-CH(R_5)-X$,

R_5 is hydrogen, $-(CH_2)_2-OH$, $-(CH_2)_3-OH$, $-CH_2-OH$, $-CH(CH_3)-OH$, isobutyl or benzyl

X is a group of formula $-COOR_1$, $-CH_2OR_2$ or



wherein

R_1 and R_2 have the meanings given above,

R_6 is hydrogen or C_{1-3}alkyl and

R_7 is hydrogen, C_{1-3}alkyl, phenyl or C_{7-10}phenylalkyl,

the group $-CH(R_5)-X$ having the D- or L- configuration, and Y_1 and Y_2 are each hydrogen or together represent a direct bond, whereby the residues in the 1- and 6-position each independently have the L- or D-configuration.

34. A pharmaceutical composition according to ~~any of Claims 1 to 4~~ Claim 1, wherein the somatostatin analog is a compound of formula

A'



A

wherein

A is C_{1-12}alkyl, C_{7-10}phenylalkyl or a group of formula RCO-, whereby

i) R is hydrogen, C_{1-11}alkyl, phenyl or C_{7-10}phenylalkyl or

ii) RCO- is

a) an L- or D-phenylalanine residue optionally ring-substituted by F, Cl, Br, No_2, NH_2, OH, C_{1-3}alkyl and/or C_{1-3}alkoxy;

b) the residue of a natural or synthetic α-a-mino acid other than defined under a) above or of a corresponding D-amino acid, or

c) a dipeptide residue in which the individual amino acid residues are the same or different and are selected from those defined under a) and/or b) above,

C_{1-8}alkanoyl,

A' is hydrogen,

Y_1 and Y_2 represent together a direct bond or each of Y_1 and Y_2 is independently hydrogen or a radical of formulae (1) to (5).



(1)



(2)

(3)



(4)



(5)

wherein

R_a is methyl or ethyl

R_b is hydrogen, methyl or ethyl

m is a whole number from 1 to 4

n is a whole number from 1 to 5

R_c is (C_{1-6})alkyl

R_d represents the substituent attached to the α-carbon atom of a natural or synthetic α-amino acid (including hydrogen)

R_e is (C_{1-5})alkyl

R_a' and R_b' are independently hydrogen, methyl or ethyl,

R_8 and R_9 are independently hydrogen, halogen, (C_{1-3})alkyl or (C_{1-3})alkoxy,

P is 0 or 1,

q is 0 or 1, and

r is 0, 1 or 2,

B is -Phe- optionally ring-substituted by halogen, NO_2, NH_2, OH, C_{1-3}alkyl and/or C_{1-3}alkoxy (including pentafluoroalanine), or ß-naphthyl-Ala

C is (L)-Trp- or (d)-Trp- optionally α-N-methylated and optionally benzene-ring-substituted by halogen, NO_2, NH_2 OH, C_{1-3}alkyl and/or C_{1-3} alkoxy,

D is Lys, Lys in which the side chain contains O or S in ß-position, F-Lys or δF-Lys, optionally α-N-methylated, or a 4-aminocyclohexylAla or 4-aminocyclohexylGly residue

E is The, Ser, Val, Phe, Ile or an aminoisobutyric or aminobutyric acid residue

G is a group of formula

$-COOR_7$, $-CH_2OR_{10}$, $-CON(R_{11})(R_{12})$ or



wherein

R_7 is hydrogen or C_{1-3}alkyl,

R_{10} is hydrogen or the residue of a physiologically acceptable, physiologically hydrolysable ester,

R_{11} is hydrogen, C_{1-9}alkyl, phenyl or C_{7-10}phenyl-alkyl,

R_{12} is hydrogen, C_{1-3}alkyl or a group of formula $-CH(R_{13})-X_1$,

R_{13} is CH_2OH, $-(CH_2)_2-OH$, $-(CH_2)_3-OH$, or $-CH(CH_3)OH$ or represents the substituent attached to the α-carbon atom of a natural or synthetic α-amino acid (including hydrogen) and

X_1 is a group of formula $-COOR_7$, $-CH_2OR_{10}$ or



wherein

R_7 and R_{10} have the meanings given above,

R_{14} is hydrogen or C_{1-3}alkyl and

R_{15} is hydrogen, C_{1-3}alkyl, phenyl or C_{7-10}phenylalkyl, and

R_{16} is hydrogen or hydroxy,

with the proviso that

when R_{12} is $-CH(R_{13})-X_1$ then R_{11} is hydrogen or methyl,

wherein the residues B, D and E have the L-configuration, and the residues in the 2-and 7-position and any residues Y_1 4) and Y_2 4) each independently have the (L)- or (D)- configuration.

35. A pharmaceutical composition according to any of Claims 1 to 4, wherein the analog is a somatostatin analog selected from the compounds of the following formulae



wherein

W is	S or $(CH_2)_s$ where s is 0, 1 or 2;
one of X and Z	is S and the other is S or CH_2;
Y is	S or $(CH_2)_t$ where t is 0, 1 or 2;
each of R_1 and R_2	independently of the other, is C_{1-5} alkyl, benzyl, benzyl having one or two C_{1-5} alkyl, halogen, hydroxy, amino, nitro, and/or C_{1-5} alkoxy substituents, or C_{1-5} alkyl substituted with 5- or 6-membered heterocyclic ring;
R_3 is	3-indolymethyl, either unsubstituted or having C_{1-5} alkyl, C_{1-5} alkoxy or halogen substitution;
R_4	C_{1-5} alkyl, C_{1-5} hydroxyalkyl, benzyl, carboxy-(C_{1-5} alkyl), amino (C_{1-5} alkyl) or benzyl having a C_{1-5} alkyl, halogen, hydroxy, amino, nitro and/or C_{1-5} alkoxy substituent;
R_5 is	C_{1-5} alkyl, benzyl, or benzyl having a C_{1-5} alkyl, halogen, hydroxy, amino, nitro, and/or C_{1-5} alkoxy substituent,

compounds of formula



wherein

A is C_{1-12} alkyl, C_{7-10} phenylalkyl or a group of formula RCO-, whereby

i) R is hydrogen, C_{1-11} alkyl, phenyl or C_{7-10} phenylalkyl, or

ii) RCO-is

a) an L- or D-phenylalanine residue optionally ring-substituted by F, Cl, Br, NO_2, NH_2, OH, C_{1-3} alkyl and/or C_{1-3} alkoxy

b) the residue of a natural α-amino acid other than defined under a) above or of a corresponding D-amino acid, or

c) a dipeptide residue in which the individual amino acid

residues are the same or different and are selected from those defined under a) and/or b) above, the α-amino group or amino acid residues a) and b) and the N-terminal amino group of dipeptide residues c) being optionally mono- or di-C_{1-12} alkylated,

A′ is hydrogen or, when A is C_{1-12} alkyl or C_{7-10} phenylalk- also C_{1-12} alkyl or C_{7-10} phenylalkyl,

Y_1 and Y_2 represent together a direct bond or

each of Y_1 and Y_2 is independently hydrogen or a radical of the formulae



(1)



(2)

(3)

(4)



(5)

wherein R_a is methyl or ethyl

R_b is hydrogen, methyl or ethyl

m is a whole number from 1 to 4

n is a whole number from 1 to 5

R_c is (C_{1-6})alkyl

R_d represents the substituent attached to the α-carbon atom of a natural α-amino acid (including hydrogen)

R_e is (C_{1-5})alkyl

R_a' and R_b' are independently hydrogen, methyl or ethyl,

R_8 and R_9 are independently hydrogen, halogen, (C_{1-3})alkyl or (C_{1-3})alkoxy,

p is 0 or 1,

q is 0 or 1, and

r is 0, 1 or 2,

B is -Phe- optionally ring-substituted by halogen, No_2, NH_2,

OH, C_{1-3}alkyl and/or C_{1-3}alkoxy, or naphthylalanine.

C is (L)-Trp- or (D)-Trp- optionally α-N-methylated and optionally benzene-ring-substituted by halogen, No_2, NH_2, OH, C_{1-3} alkyl and/or C_{1-3} alkoxy,

D is -Lys-, ThiaLys, F-Lys, δF-Lys or Orn, optionally α-N-methylated, or a 4-aminocyclohexyl Ala or 4-aminocyclohexyl Gly residue,

E is Thr, Ser, Val, Phe, Ile or an aminoisobutyric acid residue

F is a group of formula $-COOR_7$, $-CH_2OR_{10}$, $-CON(R_{11})(R_{12})$ or



wherein R_7 is hydrogen or C_{1-3}alkyl,

R_{10} is hydrogen or the residue of a physiologically acceptable,physiologically hydrolysable ester,

R_{11} is hydrogen, C_{1-3}alkyl, phenyl or C_{7-10}-phenylalkyl,

R_{12} is hydrogen, C_{1-3}alkyl or a group of formula $-CH(R_{13})-X_1$,

R_{13} is CH_2OH, $-(CH_2)_2-OH$, $-(CH_2)_3-OH$, or $-CH(CH_3)OH$ or represents the substituent attached to the α-carbon atom of anatural α-amino acid (including hydrogen) and

X_1 is a group of formula $-COOR_7$, $-CH_2OR_{10}$ or



wherein

R_7 and R_{10} have the meanings given above,

R_{14} is hydrogen or C_{1-3}alkyl and

R_{15} is hydrogen, C_{1-3}alkyl, phenyl or C_{7-10}phenylalkyl, and

R_{16} is hydrogen or hydroxy,

with the proviso that

when R_{12} is $-CH(R_{13})-X_1$ then R_{11} is hydrogen or methyl,

wherein the residues B, D and E have the L-configuration, and the residues in the 2- and 7-position and any residues Y_1 4) and Y_2 4) each independently have the (L)- or (D)-configuration and compounds of the following formulae

H-Cys-Phe-(D)Trp-Lys-Thr-Phe-Cys-OH

-Asn-Phe-Phe-(D)Trp-Lys-Thr-Phe-Gaba-

-MeAla-Tyr-(D)Trp-Lys-Val-Ph

NMe-Phe-His-(D)Trp-Lys-Val-Ala.

36. A pharmaceutical composition according to any of Claims 1 to 4, wherein the analogs are Somatostatin analogs

X-Cys-D-o-Trp-E-F-Cys-Y I

X-Cys-Lys-Asn-Phe-D-o-Trp-E-F-Phe-Thr-Ser-Cys-Y II

I,II, X = N-terminus anchor; Y = C-terminus anchor, G-I or its alc; wherein at least I of X, Y = cationic anchor; D = Phe Tyr, 3-(p-fluorophenyl)alanine or 3 (p-chlorophenyl)alanine residue; E = Lys, Lys(R^1); R^1 = C_{1-8}(fluoro)alkyl; F = Thr, Val, Ser; G = D- or L-Thr, Phe, or 3-(2-naphthyl)alanine residue; I = OH, NH_2, NHR^1.

37. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analogs are peptides:
$RR^1NCHR^2CONHCH(CH_2SR^4)CO$-Phe-Trp-Lys-X-$NHCHR^3CH_2SR^5$
[R = inorg. or org. acyl group, R^1 = H, alkyl, $NCHR^2CO$ moiety = I.

$Me(CH_2)_8CO$-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-ol I

or D-Phe (optionally ring substituted by halo, NO_2, OH, alkyl. alkoxy); Phe, Trp, (D or L) ,may be ring substituted by NO_2, NH_2, OH, alkyl, alkoxy; Lys may be α-N-methylated and Σ-N-alkylated; X = D- or L-α-amino acid residue optionally α-N-methylated; R^3 = CO_2H, CH_2OH, carbamoyl, R^4 = R^5 = H, R^4R^5

= bond]

38. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-X-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly

Cys-X^1-x^2-Phe-Phe-D-Trp-Lys-Tys-Thr-X^3-X^4-X^5-X^6-OH

39. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Leu-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-

Cys-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr-Thr-Ser-Cys-OH

40. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is
c(Spacer-Phe-D-Trp-Lys-Thr)
Spacer may stand for:
a) R,S-δ-Bn-o-AMPA
b) R-α-Bn-NMe-o-AMPA
c) Phe-Pro

41. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
H_2N-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH

42. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
H_2N-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys-OH

43. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatim analog is:
D-ß-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2

44. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
Ac-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2

45. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Trp-NH_2

46. A pharmaceutical composition according to any of Claims 1 to

4, wherein the somatostatin analog is:
D-Trp-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr-NH_2

47. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2

48. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH_2

49. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
3-(2-naphthyl)-D-Ala-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH_2

50. A pharmaceutical composition according to any of Claims 1 to 4, wherein the somatostatin analog is:
c(Aha-Phe-p-Cl-Phe-D-Trp-Lys-Thr-Phe)
Aha = 7 -amino heptanoic acid.

51. A pharmaceutical composition according to any of Claims 1 to 4, wherein the active ingredient is diazoxide and comprises in addition a thiazide selected among chlorothiazide, hydrochlorothiazide, trichloromethiazide and polythiazide.

52. A method for the treatment of symptoms of syndrome X by applying to a patient a pharmaceutical composition according to any of Claims 1 to 51 comprising a pharmaceutically effective dosage of a compound selected among somatostatin or one of its analogs (as herein defined), diazoxide or one of its analogs (as herein defined), cyclothiazideor one of its analogs(as herein defined) and metformin.

53. A method according to Claim 52, wherein the pharmaceutically effective dosage (calculated on octreotide) does not exceed 50μ/kg/day.

54. A method according to Claim 53, wherein said dosage does not exceed 40μ/kg/day.

55. A method according to any of Claims 52 to 54 wherein the analog is Octreotide which is applied in the form of an injection in a 0.9% saline solution.

56. A method according to Claim 52, wherein said dosage does not exceed 8 mg/kg/day in the treatment of the active ingredient (calculated on diazoxide) in adults, and does not exceed 15/mg/day in the treatment of children.

57. A method according to Claim 52, wherein the amount of metformin applied does not exceed 2.5 g/day divided into 2 - 3 portions.

58. Use of a compound selected among somatostatin or one of its analogs (as herein defined), diazoxide or one of its analogs (as herein defined), cyclothiazide or one of its analogs(as herein defined) and metformin in a preparation for the treatment of the risk factors of syndrome X of Reaven substantially as described in the specification.

ADD D2